வணிகரீதியானது மைல்கற்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வணிகரீதியானது மைல்கற்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வணிகரீதியானது மைல்கற்கள் Today - Breaking & Trending Today

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update
ATUs in France
in Europe in H1 2022
Successful refinancing in Q1 2021 secures mid-2023 runway
Multiple regulatory and clinical milestones expected in Q4 2021
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2021 and provided recent operational updates. The full interim financial report is available on the Company s website in the Investors section. The 2021 half-year financial statements were subject to a limited review by the Company s statutory auditors and approved by the Board of Directors on July 28, 2021. ....

United Kingdom , United States , James Palmer , Gensight Biologics Euronext , Gensight Biologics , Bernard Gilly , Thomas Gidoin , Guillaume Van Renterghem , Jeanene Timberlake , Research Tax Credit , European Medicines Agency , European Commission , Drug Administration , Access Program , Sales Marketing , Sight Biologics , North America , Chief Executive Officer , Leber Hereditary Optic Neuropathy , Year Financial , Chief Financial Officer , Temporary Authorization , French National Drug Safety Agency , Agence Nationale , Marketing Authorisation Application , Tax Credit ,

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Dennis Mulroy , Hamza Suria , Bristol Myers Squibb , Anaptysbio Inc , European Commission , Drug Administration , Tesaro Inc , Exchange Commission , Clinical Development , Antibody Under Clinical Development , Solid Tumors , Anaptysbio Generated Antibody , Under Clinical Development , Obtain Regulatory Approval , Payment Earned , Anaptysbio Upon , Due Upon Dostarlimab Regulatory , Commercial Milestones , Bio Due , Global Net Sales , Marketing Authorisation Application , Product Characteristics , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , ஹம்ஸா சூரியா ,